IZIFUNDO ZETYALA EZIKHOYO
I-CAR-T yeGlioblastoma
I-Glioblastoma yenye yezona tumors ziqhelekileyo nezinzima kakhulu kubantu abadala. Ivela kwiiseli ze-glial engqondweni kwaye yaziwa ngokukhula kwayo ngokukhawuleza kunye nokuthambekela kokungena kwizicwili ezijikelezileyo, okwenza kube nzima ukususwa ngokupheleleyo. Iimpawu zinokubandakanya iintloko ezibuhlungu, ukuxhuzula, utshintsho lokuqonda, kunye nokungasebenzi kakuhle kwemithambo-luvo, kuxhomekeke kwindawo ekuyo i-tumor. Nangona unyango oluqhelekileyo lunokunceda ukulawula isifo, izigulane ezininzi zifuna unyango olujoliswe kuzo ukuphucula iziphumo kunye nomgangatho wobomi.
Unyango lwe-CAR-T lomhlaza wesisu
Unyango lweeseli zeCAR-T lunyango oluphambili olulungiselelwe wena olusetyenziswa ngokukhutheleyo kunyango lomhlaza wesisu. I-BIOOCUS iphuhlise iimveliso zeCAR-T ezijolise kwii-antigens ezithile zomhlaza wesisu ezifana neClaudin18.2 kunye neHER2, zibonisa ukusebenza kakuhle kwizigulana eziye zasilela kunyango oluninzi lwangaphambili—umzekelo, i-CT041 ifumene i-ORR ye-57.1%, i-DCR ye-75%, kunye nenqanaba lokusinda leenyanga ezi-6 le-81.2%. Isebenzisa iqonga le-GMP lamazwe ngamazwe, iqela leengcali ezininzi, kunye namava amaninzi eklinikhi yehlabathi, i-BIOOCUS ibonelela ngesisombululo sonyango lweCAR-T esikhuselekileyo, esisebenzayo, nesibanzi kwizigulana ezinomhlaza wesisu.
I-CAR-T yeSystemic Lupus Erythematosus (SLE)
Unyango lweeseli ze-CAR-T (Chimeric Antigen Receptor T) lunyango oluphambili lwe-immunotherapy olubonakalise amandla okunyanga i-SLE ngokujolisa kwiiseli ze-B, ezidlala indima ebalulekileyo kwi-pathogenesis yesi sifo. Kwi-SLE, iiseli ze-B zivelisa ii-autoantibodies ezihlasela izicubu zomzimba, nto leyo ekhokelela ekuvuvukeni okungapheliyo kunye nomonakalo wamalungu omzimba. Unyango lwe-CAR-T lusebenza ngobunjineli beeseli ze-T ukuveza i-receptor (CAR) ejolisa ngokukodwa kwi-CD19, uphawu kwiiseli ze-B, nto leyo ekhokelela ekutshatyalalisweni kwezi seli ze-B eziyingozi.
Iiseli ze-CAR-T ezijolise kwiiseli ze-CD19+ B zibonelela ngokuncipha okusebenzayo nokuqhubekayo kweeseli ze-B xa kuthelekiswa nezinye iindlela zonyango, ezijolise kwi-CD20 kodwa ziyasilela ekupheliseni iiseli ze-plasma ezihlala ixesha elide. Oku kuncipha okukhulu kweeseli ze-B kunokukhokelela ekuxolelweni kweempawu ze-SLE ngokuphelisa iiseli ezinoxanduva lokuvelisa ii-autoantibodies. Izifundo zikwahlola i-CAR-Treg (iiseli ze-CAR-T ezenzelwe ukulawula iimpendulo zomzimba) ukubuyisela ukunyamezelana komzimba kunye nokunciphisa umsebenzi wokuzikhusela komzimba.
I-FUCASO: Unyango lwe-BCMA CAR-T oluGuqukileyo oluSebenza ngokuPheleleyo kunye noKhuseleko olungenakuthelekiswa nanto
I-FUCASO lunyango lwe-CAR-T olujolise kwi-BCMA oluvela kwi-IASO BIO, olunikezela ngokusebenza okumangalisayo kunye nokhuseleko kwi-myeloma ephindaphindayo okanye enganyangekiyo. Ngamazinga aphezulu okusabela, ukuphumla okuhlala ixesha elide, kunye neprofayili yokhuseleko eqinileyo, i-FUCASO inika ithemba elitsha kwizigulana kwaye imisela umgangatho omtsha kunyango lwe-CAR-T.
Inkcazelo Epheleleyo Yonyango Oluqhekezayo Lwe-Leukemia
I-CAR-T Therapy, isifinyezo segama elithi Chimeric Antigen Receptor T-Cell Immunotherapy, yindlela yonyango oluphucukileyo lwezakhi zofuzo equka ukuguqula izakhi zofuzo zeeseli ze-T zesigulana ukuze zijolise kwaye zitshabalalise iiseli zomhlaza. Ngokungafaniyo namayeza emveli, unyango lwe-CAR-T lulungiselelwe isigulana ngasinye kwaye lufuna ukuqokelela iiseli ze-T egazini lesigulana ngaphambi kokuba ziphinde zifakwe emzimbeni emva kobunjineli bezakhi zofuzo.